Background
The accumulation of eosinophils in lung tissue is a hallmark of asthma, and it is believed that eosinophils play a crucial pathogenic role in allergic inflammation. Prostaglandin (PG) E 2 exerts anti-inflammatory and bronchoprotective mechanisms in asthma, but the underlying mechanisms have remained unclear. We have shown previously that PGE 2 and the EP 2 receptor agonist butaprost inhibit eosinophil trafficking in vitro and in vivo.
Methods
Human eosinophils were purified by negative magnetic selection from peripheral blood. Cell migration was determined in microBoyden chemotaxis chambers. Ca 2+ flux and expression of cell surface markers was recorded by flow cytometry. EP 4 receptor expression was demonstrated by immunostaining.
Results
The chemotaxis of eosinophils towards eotaxin and C5a was attenuated by the EP 4 agonist ONO-AE1-329, and the EP 4 antagonists ONO-AE3-208 and GW627368x partially reversed the inhibitory effect of PGE 2 on eosinophil migration. ONO-AE1-329, and also PGE 2 , but not butaprost, inhibited the Ca 2+ flux and the production of reactive oxygen species in eosinophils. ONO-AE1-329 also inhibited eosinophil degranulation and the up-regulation of the adhesion molecule CD11b. Selective kinase inhibitors revealed that the inhibitory effect of EP 4 stimulation on eosinophil migration depended upon activation of phosphatidylinositol 3-kinase and protein kinase C, but not cAMP. Immunostaining showed that human eosinophils express EP 4 receptors and that EP 4 receptor expression in the murine lungs is prominent in airway epithelium, and after allergen challenge, in peribronchial infiltrating leukocytes.
Conclusion
These data show that EP 4 receptor agonists potently inhibit eosinophil trafficking and activation, and might hence be a useful therapeutic option in eosinophilic diseases. 
